Gaudium IVF & Women Health IPO Details
Gaudium IVF & Women Health IPO Summary
Gaudium IVF & Women Health IPO opens for subscription on 20 Feb 2026 and closes on 24 Feb 2026.The IPO will be listed on NSE, BSE with the tentative listing date set for 27 Feb 2026.
Gaudium IVF & Women Health IPO price band has been fixed at ₹75 – ₹79 per share. The face value is ₹5 per share with a lot size of 189.
Gaudium IVF & Women Health IPO total issue size comprises 2,08,86,200 shares (aggregating up to ₹165.00 Cr). This includes a fresh issue of 1,13,92,500 shares (aggregating up to ₹90.00 Cr). Offer for Sale consists of 94,93,700 shares (aggregating up to ₹75.00 Cr). Pre-issue shareholding stands at 6,13,94,384, which will increase to 7,27,86,884 post-issue.
Gaudium IVF & Women Health IPO carries a ₹0 (0%) GMP, reflecting investor sentiment.
Gaudium IVF & Women Health IPO Lot Size :Retail Minimum is 1 lot (189 shares) amounting to ₹14,931. Retail Maximum is 13 lots (2,457 shares) amounting to ₹194,103. SHNI Minimum is 14 lots (2,646 shares) amounting to ₹209,034. SHNI Maximum is 66 lots (12,474 shares) amounting to ₹985,446. BHNI Minimum is 67 lots (12,663 shares) amounting to ₹1,000,377.
Gaudium IVF & Women Health IPO Details
Gaudium IVF & Women Health IPO Subscription
Gaudium IVF & Women Health IPO Application Wise Breakup (Approx)
Gaudium IVF & Women Health IPO Dates
- 20 Feb 2026Opening dateOpen
- 24 Feb 2026Closing dateClose
- 25 Feb 2026Allotment Date Allotment
- 25 Feb 2026Initiation of RefundsRefund
- 25 Feb 2026Credit of SharesCredit
- 27 Feb 2026Listing dateListing
Gaudium IVF & Women Health IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 189 | ₹14,931 |
| Retail Maximum | 13 | 2457 | ₹194,103 |
| SHNI Minimum | 14 | 2646 | ₹209,034 |
| SHNI Maximum | 66 | 12474 | ₹985,446 |
| BHNI Minimum | 67 | 12663 | ₹1,000,377 |
Gaudium IVF & Women Health IPO Reservation
Promoter Holding
Documents
Gaudium IVF & Women Health IPO Valuations
Gaudium IVF & Women Health Financial Information
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 106.62 | 88.51 | 51.01 | 36.63 |
| Total Income | 49.75 | 70.96 | 48.15 | 44.26 |
| Profit After Tax | 12.51 | 19.13 | 10.32 | 13.53 |
| EBITDA | 18.95 | 28.63 | 19.27 | 20.07 |
| NET Worth | 58.85 | 46.30 | 26.99 | 22.73 |
| Reserves and Surplus | 28.16 | 15.60 | 26.00 | 21.74 |
| Total Borrowing | 22.51 | 18.93 | 15.73 | 9.78 |
| Amount in ₹ Crore | ||||
About Gaudium IVF & Women Health IPO
Incorporated in March 2015, Gaudium IVF and Women Health Limited have engaged in In Vitro Fertilization (IVF) treatments throughout India and have expanded into several states utilizing a hub-and-spoke model.
The company operates over thirty locations, which include seven hubs (centres) and twenty-eight spokes. The organization has entered into a strategic alliance with Infertility Experts, known as Spokes, to achieve the mutual objective of raising awareness regarding Assisted Reproductive Technology (ART) and In Vitro Fertilization (IVF) treatments.
The company serves patients from various countries, including Canada, the United Kingdom, the United States, Kenya, South Africa, and Oman.
The company has centres in major cities: two in Delhi (Janakpuri, Kailash Colony), and one each in Mumbai (Khar West), Ludhiana, Srinagar, Patna, and Bangalore, covering key locations across India.
The company offers specialized fertility services, including In Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI), Intrauterine Insemination (IUI), and ovulation induction. Our treatments are designed for various infertility challenges for both genders. We also provide comprehensive gynaecological care for PCOD/PCOS and endometriosis, as well as high-risk pregnancy management for women with complex fertility histories or health conditions.
Strength Of Gaudium IVF & Women Health IPO
- Clinical excellence and advanced medical technologies to deliver quality healthcare.
- Ability to attract, train and retain high-quality doctors and staff.
- Scalable model and disciplined approach for growth.
- Stable and robust financial performance.
- Professional management and experienced leadership of our Promoters i.e., Manika Khanna and Peeyush Khanna.
Risk Of Gaudium IVF & Women Health IPO
- The Company is in engaged in the business of providing healthcare services mainly rendering various fertility treatments such as In Vitro Fertilization (IVF), intrauterine insemination (IUI), intracytoplasmic sperm injection (ICSI), Egg Freezing, laser assisted embryo implantation amongst others and is subject to various operational, reputational, medical and legal risks associated with the operations of healthcare services. An inability to provide quality healthcare catering to the needs of the customers could adversely affect the reputation, business prospects and financial performance of the Company.
- The Company may highly dependent on doctors, nurses and other healthcare professionals and the business will be impacted significantly if the Company is unable to attract / retain such professionals.
- The business of the Company depends on the strength of the brand and reputation of the Company. Failure to maintain and enhance the brand and reputation, and any negative publicity and allegations in the media against the Company, even if untrue, may adversely affect the brand, reputation and trust in, services of the Company, which could result in a material adverse impact on business, financial condition, results of operations and prospects of the Company.
- The Company may face challenges in further expanding operations in cities where the Company currently operate in or in other cities that the Company strategically intend to commence operations, which could have an adverse effect on the business prospects and future financial performance.
- Our Company has experienced negative cash flows in the past. We cannot assure you that we will achieve or sustain profitability and not continue to incur losses going forward.
- The failure to identify, understand and adapt to rapidly evolving technological advancements related to our medical equipment and technology could adversely affect our business prospects and financial performance.
- If the Company fails to achieve favourable pricing from its suppliers or vendors, fail to negotiate favourable terms with its doctors, or fail to pass on any cost increases to the customers, its business, financial condition and profitability may be adversely impacted.
- Failure or malfunction of our medical or other equipment, could adversely affect our ability to conduct our operations.
- Proposed New IVF Centres of the Company may experience delays in construction, development and completion. Any delays in New IVF Center setup, due to unforeseen events, may lead to cost overruns and implementation delays, impacting our business growth.
- For our business, we rely heavily on our Promoters namely, Dr. Manika Khanna and Dr. Peeyush Khanna. Our business performance may have an adverse effect by their departure or by our failure to recruit or keep them.
Objectives Gaudium IVF & Women Health IPO
1. Funding capital expenditure towards establishment of New IVF Centers of the Company.
2. Repayment/pre-payment, in full or in part, of certain outstanding loans availed by the Company.
3. General Corporate Purpose
4. Total
Company Contact Details
Gaudium IVF & Women Health Ltd.
B1/51,
Janak Puri,
B-1,
New Delhi, New Delhi, 110058
Phone: 011-4885 8585
Email: compliance@gaudiumivfcentre.com
Website: https://www.gaudiumivfcentre.com/
Registrar Contact Details
Gaudium IVF & Women Health FAQs
The Gaudium IVF & Women Health IPO is a MAINBOARD public issue comprising 20886200 equity shares with a face value of ₹5 each, aggregating to a total issue size of ₹165.00 Cr. The issue price has been fixed at ₹79 per equity share, and the minimum application size is 189 shares.
The IPO opens for subscription on 20 Feb 2026, and closes on 24 Feb 2026.
Bigshare Services Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
As of now, the current GMP stands at ₹0 (0%).
Quick Links
Comments
